Table 1.
Panel showing laboratory data of two cases after COVID-19 infection
| Tests* | Case 1 | Case 2 | Reference range |
|---|---|---|---|
| White blood cells | 3890 | 3600 | 3500–10,500 (μL) |
| Lymphocytes | 1120 | 940 | 1090–2900 (μL) |
| Neutrophil | 2530 | 1990 | 1800–7000 (μL) |
| CD4/CD8 | 1.59 | 0.94 | 0.8–3.9 |
| CD19 | 0.70 | 3.10 | 7–23 (%) |
| CD20 | 0.70 | 3.20 | 6–23 (%) |
| IgA | 1.98 | 2.01 | 0.46–2.21 (g/L) |
| IgM | 2.17 | 0.644 | 0.45–1.98 (g/L) |
| IgG | 15 | 6.29 | 7.3–16.20 (g/L) |
| IL-6 | 5.98 | NA | 0–3.4 (pg/mL) |
| Anti-SARS-CoV-2-IgG** | 3.19 (3rd week) |
Negative (3rd week) Positive (9th week) |
< 1.4 |
*These data were obtained on the same day the last cladribine tablet was given and after the RT-PCR swab test came positive for COVID-19 infection for case 1 and on the 35th day for case 2
**For case 1, the anti-SARS-CoV-2-IgG test used was chemiluminescent microparticle immunoassay (CMIA) from Abbott Diagnostics which is a 2-step qualitative assay detecting in serum or plasma IgG antibodies against the SARS-CoV-2 nucleocapsid protein, performed on an Architect i2000. For case 2, the test used was ELISA based with a positive value being over 6